Researchers from Abbvie Inc. have reported on the discovery and optimization of a series of selective tyrosine kinase 2 (TYK2) inhibitors that led to the identification of ABBV-712 as the lead compound.
Newco T-Therapeutics Ltd. has raised £48 million (US$59 million) in a series A to advance development of T-cell receptors generated by its transgenic mouse platform for the treatment of solid tumors, autoimmune diseases and infections. In cancer, the specificity of T-Therapeutics’ molecules will overcome shortcomings of immuno-oncology drugs such as checkpoint inhibitors that stimulate a response to some cancer neo-antigens but are unable to recognize cancer-specific self-antigens.
Researchers from Kyverna Therapeutics Inc. have presented data on their anti-CD19 CAR T-cell therapy, KYV-101, for the treatment of B-cell-driven autoimmune diseases.
Emergex Vaccines Holding Ltd. has signed a contract with the U.K. Department of Health and Social Care (DHSC) for almost £1.8 million (US$2.2 million) to advance a CD8 T cell-based vaccine candidate against Chikungunya virus (CHIKV).
Nonreceptor tyrosine-protein kinase TYK2 plays key roles in the signaling of pro-inflammatory molecules such as IL-23, IL-12 or type I IFN, which at the same time play key roles in several immune-mediated diseases such as atopic dermatitis and psoriasis, among others.
Scirhom GmbH has submitted a clinical trial application (CTA) for its lead candidate, SR-878, an antibody designed to target inactive rhomboid protein 2 (iRhom2) as a therapeutic strategy for numerous autoimmune disorders.
There is increasing evidence on the involvement of Toll-like receptor 7 (TLR7) in the pathogenesis of systemic lupus erythematosus (SLE). At the recent American College of Rheumatology meeting, researchers from Daiichi Sankyo Co. Ltd. presented preclinical data on DS-7011a, a TLR7 antagonist antibody with for the potential treatment of SLE.
Scientists at the University of California San Francisco (UCSF) have designed a group of synthetic molecules that could prevent the rejection of allogeneic cell transplants. Their strategy consisted of activating the immune checkpoints of different populations of immune cells from the cell surface, but avoiding the cytotoxicity of natural killer (NK) cells and macrophages that would destroy the transplanted cells.
RSS
